Find innovation, content, and partners at DDP14

partneringONE® allows you to connect with hundreds of attendees across the entire drug delivery ecosystem to find new potential partners and meet companies that fit your criteria for your next multi-million dollar deal. Efficiently plan your DDP agenda, from the pre-event invitations to the final handshakes on-site, to be more productive than ever. Conduct more face-to-face meetings here than in the rest of the year and jump-start your next big strategic partnerships. 

Meet the 2014 Highlighted Speaking Faculty: 

• Alfred Mann, CEO, MannKind Corporation 

• Fernando Sallés, PhD, CLP, Executive Director, Strategic Licensing & Acquisitions Lead Ophthalmics and Drug Delivery Technology, Merck Research Laboratories 

• Michelle M. Marciniak, Co-Founder and Co-CEO, SHEEX, Inc. (on behalf of the Pat Summit Foundation) 

Hear additional speakers from:

Abbvie*Allergan*Amgen*Amylin*AstraZeneca*BD Medical*Bend Research*Biogen Idec*BioMedcial Research, Inc.*Blue Fin Health Group*Bristol-Meyers Squibb*Cambridge Consultants*Catalent Pharma Solutions*Christopher Rhodes & Associates* Eisai Inc.*Eli Lilly and Company*Enable Injections, LLC*European Federation for Pharmaceutical Sciences*Flextronics Medical*Florida International University*Genetech*Genisphere*GlaxoSmithKline*Hospira,Inc.*iCeutica*Janssen*MedImmune*Nanomi*Nissen Consulting Group*Novartis*Novozymes BioPharma UK*Patheon*Pfizer*Phillip Morris International*Purdue Pharma*P/L Biomedical*Sanofi*Sensile Medical AG*Unilife*West Pharmaceutical Services*3M Drug Delivery System Division 

To view our full program, download our agenda. 

Use code XP1978BLOG to register today and you’ll save 15%. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage. We look forward to seeing you this January! 

Cheers, 

The Drug Delivery Partnerships International Team 

Opt-in for updates 

Follow us on Twitter

Join our LinkedIn group

Session Spotlight: Industry and Academia Drug Delivery Partnerships in Europe through the ORBITO Project

Most drugs are taken orally, as tablets or capsules. However, designing these pharmaceutical products in such a way that the active ingredient is absorbed at an appropriate rate and extent by the gut is far from easy. So how can we better understand this process as a whole?


Session: Industry and Academia Drug Delivery Partnerships in Europe through the ORBITO Project

Speaker: Clive G. Wilson, JP Todd Professor of Pharmaceutics, University of Strathclyde, Steering Committee, European Federation for Pharmaceutical Sciences

Improving the delivery capabilities of a pharma product can occur through different mediums. The ORBITO project aims to enhance the understanding of how orally administered drugs are absorbed and is driven by the collaboration of 12 pharma and 11 academic partners. Want to learn more? Join us January 27-29 in Boca Raton, FL for IIR's 18th Annual Drug Delivery Partnerships event!

To view our full program, download our agenda. As a reader of this blog you'll receive 15% off of the standard rate when you use XP1978BLOG to register. We hope to see you this January!

Two-wave delivery method helps target tumors

In order to deliver drugs to the target, you need a clear path. UCLA Researchers have discovered that by clearing the pathway using nanoparticles first, chemotherapy drugs are able to reach the cancer cells in a more precise, effective way.

So by using a dual-wave method of two different nanoparticles, injected quickly one after the other, the scientists cleared a path for the drugs to access the cells. The first wave of nanoparticles carries a signaling pathway inhibitor that removes these stroma "gates," exposing the cells, and the second wave carries the cancer drug, which then has free reign within the tumor.

The dual-wave nanotherapy is engineered to help reduce side effects, making the treatments less toxic. Is nanotherapy slowly revolutionizing the way we treat certain illnesses, especially cancer?

Want to learn more about the future of drug delivery? IIR's 18th Annual Drug Delivery Partnerships will help you form a drug delivery strategy that keeps you ahead of the market, register today! Save 15% off of the standard rate when you register using priority code XP1978BLOG. To learn more, download our agenda. We hope to see you January 27-29 in Boca Raton!

Your Sneak Peek at DDP14

Join us on January 27-29th in Boca Raton for IIR’s 18th Annual Drug Delivery Partnerships 2014. Your roadmap to success starts here—the only event that delivers the perfect mix of technology, insights and innovation. With the new additions for the 2014 program, demand is booming, feedback is positive and registrations are pouring in steadily—so save your seat today!

Here is a sneak peak of what’s NEW in 2014:

• partneringONE—Scour hundreds of attendees from across the entire drug delivery ecosystem to find new potential partners and meet companies that fit your criteria for your next multi-million dollar deal.
• Keynote Speaker Al Mann, CEO of Mannkind
• 5K Walk/Run Benefiting the Pat Summit Foundation
• Innovation Theater—Your showcase of the newest and most cutting-edge technologies, where sellers share top innovations, and buyers align them to their life cycle needs.

CONTENT FOCUS
 • Method Innovation
• Improving Outcomes
• Human Factors
• Connected Health
• Academic Partnerships
• Combination Product Development

SPEAKER & FACILITATOR HIGHLIGHTS 
• Al Mann, CEO of Mannkind
• Fernando Salles, Exec. Dir., Strategic Licensing & Acquisitions Lead, Ophthalmics and Drug Delivery Technologies, Merck Research Laboratories
• Lee Shorter, Dir., Disruptive Innovation Seeker, GSK
• Seesha Neervannan, VP, Pharmaceutical Development, Allergan

Want to learn more? Download our full agenda.

Use code XP1978BLOG to register today and you’ll save 15%. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

Cheers,
The Drug Delivery Partnerships International Team

Opt-in for updates
Follow us on Twitter
Join our LinkedIn group

New hydrogel discovery for treating breast cancer

New developments from IBM and Singapore’s Institute of Bioengineering and Nanotechnology shows that hydrogel may be the latest method for treating breast cancer. Hydrogel is non-toxic, biodegradable, biocompatible, and can also distribute the medication at a slower pace. There are three separate post-surgery methods for treating breast cancer: chemotheraphy, hormone therapy, and a monoclonal antibody treatment,  all determined by the stage, size of the tumor, and rate of growth. The antibody treatments consists of combining both the drug and saline and then delivering it intravenously. The problem with this method is that the drugs are absorbed too quickly to travel through the bloodstream, however, this hydrogel can release the drugs at a slower rate.

As an alternative, scientists have developed a novel synthetic hydrogel made up of over 96% water and a degradable polymer. The gel is capable of using a range of different drug molecules. Because the gel dissolves slowly, it can release the drugs relatively slowly, meaning that the process of providing anti-cancer drugs to the target site is more efficient.

What other types of intravenous delivery methods could hydrogel be used for? Want to learn more about the future of drug delivery?

IIR's 18th Annual Drug Delivery Partnerships will help you form a drug delivery strategy that keeps you ahead of the market, register today! Save $700 when you register by 11/15, use priority code XP1978BLOG. To learn more, download our agenda. We hope to see you January 27-29 in Boca Raton!

Human Factors Planning at DDP14 between Drug and Device Partners

FACT: The drug delivery technologies market will reach $224.2 billion by 2017* with the need for self-administration and home healthcare devices driving this growth.

REALITY: The FDA evaluates the Human Factors of drug devices which are now necessary for approval. Patient adherence has a $300 billion impact on healthcare, according to the New England Healthcare Institute.

PLAN OF ACTION: Join us at IIR’s 18th Annual Drug Delivery Partnerships in Boca Raton, FL this January 27-29 to learn how to engineer devices that meet Human Factor requirements as well as how to choose technologies developed with these requirements in mind.

Here are some key sessions you will hear on Human Factors at DDP14: 

Sharing Responsibilities for Human Factors – Roles and Relationships of the Drug and Device Partners Lee Leichter, President, P/L Biomedical

Managing Human Factors and Clinical Bridging for Combination Product Post-Approval Changes Sherri Biondi, Associate Director, Device Development, Genentech

Scaling of Human Factor Engineering Development Efforts for New Designs and Platform Extensions Jim Kershner, Consultant Engineer, Human Factors/ Risk Management, Delivery Device Research & Development, Eli Lilly and Company

The Challenges and Best Practices for the Integration of Human Factors Engineering into Medical Device to Address Patients’ Unmet Needs Raza Ahmed, Worldwide Director, Medical Affairs, BD Medical – Pharmaceutical Systems, Self-Administration Injection Systems

To learn more, download the agenda.

Save $700 when you register by 11/15, use priority code XP1978LINK. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

Cheers,
The Drug Delivery Partnerships International Team

Opt-in for updates
Follow us on Twitter
Visit our LinkedIn Page